Extraction, isolation, synthesis, and biological evaluation of novel piperic acid derivatives for the treatment of Alzheimer’s disease
- 23 June 2023
- journal article
- research article
- Published by Springer Nature in Molecular Diversity
- Vol. 28 (3) , 1439-1458
Abstract
In this paper, we developed a series of piperic acid (PA) analogs with the aim of overcoming the limitations associated with the natural products for the management of Alzheimer’s disease (AD). A comprehensive SAR study was performed to enhance cholinesterase inhibition of PA. The acetylcholinesterase inhibition and its kinetic data suggested 6j as the lead molecule (AChE IC50 = 2.13 ± 0.015 µM, BChE = 28.19 ± 0.20%), in comparison to PA (AChE = 7.14 ± 0.98%) which was further selected for various biological studies in AD models. 6j, exhibited interaction with the peripheral anionic site of AChE, BBB permeability (Pe = 7.98), and antioxidant property (% radical scavenging activity = 35.41 ± 1.09, 2.43 ± 1.65, for 6j and PA at 20 M\(\mu \), respectively). The result from the metal chelation study suggests that 6j did not effectively chelate iron. The molecular modeling studies suggested that 6j could effectively interact with Ser293, Phe295, Arg296, and Tyr34 of AChE. In the cell-based cytotoxicity studies, 6j exhibited cytocompatibility at the different tested concentrations. The acute toxicity data on mice suggested that compound 6j had no renal and hepatotoxicity at 500 mg/kg. Moreover, 6j could effectively reverse scopolamine-induced amnesia by improving spatial and cognitive memory in mice. The above results strongly suggest that compound 6j may act as a novel multi-targeted lead for AD therapy. Graphical abstract
Keywords
This publication has 33 references indexed in Scilit:
- Advances in Recent Patent and Clinical Trial Drug Development for Alzheimer’s DiseasePharmaceutical Patent Analyst, 2014
- g_mmpbsa—A GROMACS Tool for High-Throughput MM-PBSA CalculationsJournal of Chemical Information and Modeling, 2014
- Molecular Topology as Novel Strategy for Discovery of Drugs with Aβ Lowering and Anti-Aggregation Dual Activities for Alzheimer’s DiseasePLOS ONE, 2014
- Dopamine D2/D3 Agonists with Potent Iron Chelation, Antioxidant and Neuroprotective Properties: Potential Implication in Symptomatic and Neuroprotective Treatment of Parkinson’s DiseaseChemMedChem, 2011
- PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprintsJournal of Computational Chemistry, 2010
- Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and Its Analogues as Highly Potent Dopamine D2/D3 Agonists and as Iron Chelator: In Vivo Activity Indicates Potential Application in Symptomatic and Neuroprotective Therapy for Parkinson’s DiseaseJournal of Medicinal Chemistry, 2010
- Classics in Spectroscopy. Isolation and Structure Elucidation of Natural Products. Von Stefan Berger und Dieter Sicker.Angewandte Chemie, 2009
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Oxidative stress hypothesis in Alzheimer’s disease: a reappraisalTrends in Pharmacological Sciences, 2008
- Tetrazolium dyes as tools in cell biology: New insights into their cellular reduction2005